Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

RTTNews | 596天前

Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Pharmaceuticals Inc. (VRTX) announced Friday that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

RTTNews | 704天前

Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) and gene editing company CRISPR Therapeutics, Inc. (CRSP) announced Monday that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).

RTTNews | 967天前

Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.

RTTNews | 1232天前

Indian Shares Hold Steady Before Nvidia Earnings

Indian shares were little changed on Wednesday as investors braced for earnings from Nvidia and the release of all-important delayed U.S. jobs report.

RTTNews | 1小时26分钟前

Australian Market Trims Early Slight Gains In Mid-market

The Australian stock market is trimming its early slight gains in mid-market moves in choppy trading on Wednesday, reversing some of the sharp losses in the previous session, with the benchmark S&P/ASX 200 staying well above the 8,450 level, despite the broadly negative cues from Wall Street overnight, with gains in gold miner stocks partially offset by weakness in financial stocks.

RTTNews | 2小时30分钟前

Asian Markets Trade Mostly Higher

Asian markets are trading mostly higher on Wednesday, despite the negative cues from Wall Street overnight, as traders look to pick up stocks at a bargain following the three-day sell-off in the markets. They are also cautious ahead to the release of some US economic data that was delayed, including the September jobs report on Thursday for clues on the outlook for interest rates.

RTTNews | 2小时47分钟前

Indian Shares Seen Little Changed With Focus On Trade Deal

Indian markets look set to open on a flat note Wednesday as investors watch the latest developments on the India-U.S. trade deal.

RTTNews | 3小时14分钟前

EURUSD	1.15837	GBPUSD	1.31395	AUDUSD	0.64834
USDJPY	155.327	USDCAD	1.39975	USDCHF	0.80009